Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin

PURPOSE: Gemcitabine plus cisplatin (GemCis) is the standard first-line chemotherapy for patients with advanced biliary tract cancer (BTC). In ABC-02 study, the BTC patients received up to 6-8 cycles of 3-weekly GemCis; however, those without progression often receive more than 6-8 cycles. The clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyung, Jaewon, Kim, Bumjun, Yoo, Changhoon, Kim, Kyo-pyo, Jeong, Jae Ho, Chang, Heung-Moon, Ryoo, Baek-Yeol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639240/
https://www.ncbi.nlm.nih.gov/pubmed/30282446
http://dx.doi.org/10.4143/crt.2018.326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639240/
https://www.ncbi.nlm.nih.gov/pubmed/30282446
http://dx.doi.org/10.4143/crt.2018.326

Ejemplares similares